Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to evaluate the progression-free survival (PFS) in patients with metastatic colorectal cancer when treated with the monoclonal antibody IMC-1121B in combination with the modified FOLFOX-6 (folinic acid [FA] + fluorouracil [5-FU] + oxaliplatin, mFOLFOX-6) chemotherapy regimen as first-line therapy.
Critère d'inclusion
- Cáncer colorrectal metastásico Metastatic colorectal cancer